↓ Skip to Main Content
Thasso

Thasso

the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in | Register

Main Navigation

  • englishenglish
    • englishenglish
    • françaisfrançais
    • deutschdeutsch
    • italianoitaliano
    • españolespañol
    • portuguêsportuguês
  • thasso
  • thasso: post
  • thasso: communities
    • thasso: simple chat
    • thasso: video chat
    • thasso: forum
    • thasso: patient groups
    • thasso: online meetings (ZOOM)
  • thasso: resources
    • theragenomics: useful links
    • theragenomics: survey at thasso
      • survey participants
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: targeted therapies
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • theragenomics: videos
    • drugs: interactions
    • drugs: general information
    • drugs: adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
  • thasso: academy
    • health authorities
      • European Medicines Agency (EMA)
      • American Food & Drug Administration (FDA)
      • Swissmedic
      • FDA Ghana
      • NAFDAC Nigeria
      • CDSCO India
      • The Medicines Control Council (MCC), South Africa
      • China Food & Drug Administration (CFDA)
      • Health Canada
    • public domain
      • Clinical Pharmacogenetics Implementation Consortium
      • ACMG Genetic Test Fact Sheets
      • Public Health Genomics Knowledge Base
      • The Human Diagnosis Project
      • Phenotypes And Genotypes Database
      • Genetic Alliance UK
      • Genetics Generation
      • Front Line Genomics
      • Alliance for Cancer Gene Therapy (ACGT)
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
      • European Patient Forum
      • Uppsala Monitoring Center
      • World Health Organisation (WHO)
      • von Hippel Lindau Syndrome (VHL)
      • Cerebral Palsy Symptoms
      • Mesothelioma Fund
      • Multiple Myeloma Research Foundation
      • Open Source Pharma (OSP, Medicine for All)
    • theragenomics worldwide
      • The Human Heredity and Health in Africa (H3Africa)
      • The Asia Cohort Consortium
      • GenomeAsia 100K
    • patient & consumer health
      • ThinkGenetic
      • Consumer Health Labs
      • Exercise & Heart Disease
      • UCSF: Eating right for your heart
      • Hormones Matter
      • Living with Arthritis
      • Living with Cannabis
      • Yum of China (Foods)
    • digital therapeutics in theragenomic medicine
      • Digital Therapeutics Alliance (DTA)
      • Digital Health Alliance
    • miscellaneous
      • Partners Health Care / Personalized Medicine
      • Worst Pills / Best Pills
      • Pharmagenomics Research Network
      • Mayo Clinic: Personalized Medicine
      • Patient Power
      • Patient Opinion (UK)
      • Drug Injury Watch (Tom Lamb)
      • Ways To Fund Cancer Treatments
      • MedScape India
      • Swiss Academy of Medical Sciences
      • IDICAP: An Integrated Drug Intervention for Cancer Panel
      • PanDrugs
      • Soccer Genomics
    • companies
      • Moderna
      • BionTech
      • FDNA (Face2Gene Home)
      • IONIS Pharmaceuticals
      • Boehringer Ingelheim Home
      • Bristol-Myers Squipp Home
      • Glaxo Home
      • Novartis Home
      • Roche Home
      • AstraZeneca Home
      • Merck Home
      • Gilead Home
      • Takeda Home
      • Janssen Home
      • Novo Nordisk Home
      • Amgen Home
    • products
      • Axicabtagene ciloleucel (Yescarta)
      • Ledipasvir/Sofosbuvir (Harvoni)
      • Sofosbuvir (Sovaldi)
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Sekukinumab (Cosentyx)
      • Rivaroxaban (Xarelto)
      • Valsartan/Amlodipin/HCT (Exforge/HCT)
      • Aripiprazole (Abilify)
      • Rosuvastatin (Crestor)
      • Flibanserin (Addyi)
      • Onasemnogene abeparvovec-xioi (Zolgensma)
      • Voretigene neparvovec (Luxturna)
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • disclaimers
    • policies
    • contact
  • donations $
  • Cookie Policy (EU)
Home › Posts tagged Sinusitis

Tag: Sinusitis

Fluoroquinolone antibacterial drugs: FDA advises restricting use for certain uncomplicated infections

By Joseph Gut - thasso Posted on May 17, 2016 Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine Tagged with Advise, American Food & Drug Administration (FDA), Bronchitis, Ciprofloxacin (Cipro), Fluoroquinolones, Gemifloxacin (Factive), Levofloxacin (Levaquin), Moxifloxacin (Avelox), Ofloxacin (Oflloxacin), Sinusitis, Thasso Post, Theragenomic Medicine, Urinary Tract Infection
Fluoroquinolone antibacterial drugs: FDA advises restricting use for certain uncomplicated infections

May 17, 2016 – It has taken quite some time, but finally the American Food & Drug Administration (FDA) advises to restrict the use of fluoroquinolone antibacteril drugs for the use in certain uncomplicated infections and warns about disabling side effects that …

Fluoroquinolone antibacterial drugs: FDA advises restricting use for certain uncomplicated infections Read more »

In/Out

  • Log in

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you.    Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci.    Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.    Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie.    Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada.     Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

 

RSS FDA press releases

  • FDA, USDA and EPA Propose National Strategy to Reduce U.S. Food Loss and Waste December 4, 2023
  • FDA Roundup: December 1, 2023 December 1, 2023
  • FDA Roundup: November 28, 2023 November 28, 2023
  • FDA Cautions Public of Safety Issue with Philips’ DreamStation 2 CPAP Machines November 28, 2023
  • FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors November 27, 2023

RSS FDA MedWatch

  • Voluntary Recall of SoClean Equipment Intended for Use with CPAP Devices and Accessories: FDA Safety Communication December 4, 2023
  • Eitan Medical Ltd Recalls Sapphire Infusion Pumps for Failure to Detect Air in the Line December 1, 2023
  • Becton Dickinson (BD)/Carefusion 303 Recalls Alaris Infusion Pumps Due to Compatibility Issues with Cardinal Health Monoject Syringes December 1, 2023
  • 2023 Medical Device Recalls December 1, 2023
  • Baxter Issues Urgent Medical Device Correction for Novum IQ Syringe Infusion Pump Due to Potential Impact of Downstream Occlusions on Infusion Volume November 30, 2023

RSS EMA Press releases

  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023, PRAC, 01/12/2023 December 1, 2023
  • Consumption of antimicrobials in animals reaches lowest level ever in Europe, , 20/11/2023 November 20, 2023
  • Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 7-9 November 2023, CVMP, 10/11/2023 November 10, 2023
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023, CHMP, 10/11/2023 November 10, 2023
  • Getting ready for EMA’s website relaunch on 5 December 2023, , 09/11/2023 November 9, 2023

RSS random genetics

  • YTHDF2's role in promoting acute myeloid leukemia: The key lies in microRNA processing December 4, 2023
    In a study published in the journal Genes & Diseases, researchers from Beckman Research Institute of City of Hope, explored the impact of m6A modification on the maturation process of precursor microRNAs (pre-miRNAs) and its potential role in tumorigenesis. They have uncovered a novel mechanism behind the progression of acute myeloid leukemia (AML), a life-threatening […]
  • Research examines how protein aggregates can trigger neurodegenerative diseases December 4, 2023
    Neurodegenerative diseases are characterized by the deposition of clumped proteins in the brain and progressive neuronal cell death. Although the causal link between protein aggregates and neurodegeneration is clear, how misfolded proteins trigger cell death is not known.
  • Potential pitfalls when using the Cre-LoxP system in cancer research December 4, 2023
    A new editorial paper has been published in Oncoscience, titled, "Be mindful of potential pitfalls when using the Cre-LoxP system in cancer research."
  • Hard to drug: Protein droplets reveal new ways to inhibit transcription factors in an aggressive form of prostate cancer December 4, 2023
    Transcription factors play essential roles in turning the genetic information encoded in genes into proteins in all cells and organisms. These regulatory proteins bind DNA, turn genes on or off, and control the rate at which DNA is transcribed into mRNA, which is needed for protein synthesis.
  • Study shows leukemia cells activate cellular recycling program December 4, 2023
    In a recent study, scientists led by Professor Stefan Müller from Goethe University's Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML. The disease mainly occurs in adulthood and often ends up being fatal for older patients. In about a third of AML patients, the cancer […]

Recent Comments

  • Joseph Gut - thasso on Real world theragenomics and personalised medicine: “Thank you for your answers and invitation to join you and contribute qt some point to AUDT. I shall come…” Nov 29, 10:49
  • joannemci on Real world theragenomics and personalised medicine: “Hello Dr. Gutt – Thanks so much for your quick reply and support of my efforts to make patient safety…” Nov 28, 18:54
  • Joseph Gut - thasso on Real world theragenomics and personalised medicine: “Thanks for your comment. First of all: my heartfelt condolences on the loss of your husband. Secondly: my entire scientific…” Nov 27, 16:19
  • joannemci on Real world theragenomics and personalised medicine: “Dear Dr. Gut – As the widow of the patient you write about in this article, I want to personally…” Nov 26, 18:43
  • Joseph Gut - thasso on Is there living pharmacogenovigilance behind Semaglutide drugs?: “Of course, all the uncertainties about the “safety” of Wegovy (Semaglutid) for individual patients remain the same as those addressed…” Aug 27, 05:10

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant Allelic Variants American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Epidermal Growth Factor Receptor (EGFR) Ethnicity European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Genotype Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Footer Menu

  • englishenglish
  • thasso
  • thasso: post
  • thasso: communities
  • thasso: resources
  • thasso: academy
  • thasso: about
  • donations $
  • Cookie Policy (EU)
© 2023 Thasso | Powered by Responsive Theme
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}